Hims & Hers Health is trading at €25.40, down 6.82%, amid renewed attention on securities-fraud class-action litigation tied to FTC allegations about consumer-health data sharing, subscription billing, and cancellation practices.
- Lawsuit-related deadline coverage appeared during the week, adding legal and regulatory pressure.
- The decline also followed the September 23 risk-off session, when the Nasdaq fell 0.98% and the S&P 500 fell 0.50%.